Buy now: Price pulled back to ~34.31 near the pivot (34.435) and not far above support (S1 33.205), offering a reasonable entry for an impatient buyer.
Sentiment skewed bullish: Options open-interest positioning is heavily call-dominant (very low OI put/call), while today’s put-heavy volume looks more like short-term hedging into earnings.
Fundamentals improving: 2025/Q3 showed strong YoY EPS and net income growth, supporting the bullish analyst thesis.
Clear near-term catalyst: QDEC 2025 earnings on 2026-02-26 (pre-market) can re-rate the stock quickly if it delivers.
Technical Analysis
Trend / structure: Bullish MA stack (SMA_5 > SMA_20 > SMA_200) indicates an overall uptrend remains intact.
Momentum: MACD histogram is positive (0.116) but contracting, suggesting bullish momentum is fading short-term (risk of consolidation).
RSI: RSI_6 = 45.874 (neutral), consistent with a pullback rather than an overbought breakdown.
SwingMax: entry signal on 2026-01-22; price is up ~1.51% since then, and the current dip improves the swing entry location if support holds.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI ratio 0.07 (calls vastly outweigh puts) → strong bullish longer-horizon positioning.
Today’s flow (Volume): Put/Call volume ratio 1.17 with 41 puts vs 35 calls → short-term caution/hedging, especially after a down day.
Activity spike: Today’s option volume is ~28.36x the 30-day average → elevated attention/positioning (often seen ahead of catalysts).
Volatility: IV30 68.28 vs historical vol ~24.01 → options pricing implies large moves; however IV percentile/rank (18) suggests IV is not extreme versus its own history.
Technical Summary
Sell
3
Buy
6
Positive Catalysts
Analyst tone improving: Recent target raises and maintained bullish ratings support rerating potential.
Neutral/Negative Catalysts
Momentum cooling: MACD histogram is positive but contracting (bull trend may pause).
Financial Performance
Latest reported quarter: 2025/Q3
Revenue: $314.0M, +2.28% YoY (steady but modest top-line growth).
Gross margin: 73.57%, down 6.28% YoY (key metric to monitor—earnings growth is strong, but margin compression is a watch item).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes:
2026-01-20: Northland raised PT to $50 (from $40), kept Outperform; cites legacy overhangs resolved and valuation disconnected from fundamentals.
2025-12-03: Morgan Stanley raised PT to $36 (from $28), kept Overweight; constructive view with intact fundamentals.
Wall Street pros view (bull case): Upward estimate/target revisions, improving earnings power, and perceived undervaluation.
Wall Street cons view (bear case): Sector/valuation framing can cap upside near-term, and the stock may need an earnings beat/raise to justify a fast move higher.
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38 USD with a low forecast of 35 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38 USD with a low forecast of 35 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.450
Low
35
Averages
38
High
41
Current: 34.450
Low
35
Averages
38
High
41
Northland
Outperform
upgrade
$40 -> $50
AI Analysis
2026-01-20
Reason
Northland
Price Target
$40 -> $50
AI Analysis
2026-01-20
upgrade
Outperform
Reason
Northland raised the firm's price target on Indivior to $50 from $40 and keeps an Outperform rating on the shares. With legacy overhangs resolved, and capital allocation optionally emerging, the firm views the current valuation as "disconnected from underlying fundamentals" as it raises its FY26 revenue and adjusted EPS estimates.
Morgan Stanley
Overweight
maintain
$28 -> $36
2025-12-03
Reason
Morgan Stanley
Price Target
$28 -> $36
2025-12-03
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Indivior to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INDV
